Company / Capital Expenditures
Janux Therapeutics, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.0M
FY2025
5-year range
$359.0K / $6.4M
FY2021-FY2025
Trend
+190.5%
vs FY2024
Sector context
#111 of 192
Health Care
What the data says
At $1M, Janux Therapeutics, Inc.'s capital expenditures ranks #111 of 192 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of -45.5%.
Declined from $2M to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -45.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#111 of 192 in Health CareTop 58% of 192This company $1.0M Sector average $118.6M
▼
-99.1% below sector average
Key checks
Key Insights
- 3-year CAGR of -45.5%, indicating a declining trend.
- In FY2025, capital expenditures increased 190.5% year-over-year.
- Ranks #111 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0M | +190.5% |
| FY2024 | $359.0K | -80.6% |
| FY2023 | $1.9M | -71.3% |
| FY2022 | $6.4M | +334.9% |
| FY2021 | $1.5M | - |
| FY2020 | $0 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026